AOD-9604 Compounded Equivalent: Pricing, Access, and What You Actually Get

Why AOD-9604 Only Exists as a Compounded Product

AOD-9604 occupies an unusual position in the peptide therapy space. Unlike semaglutide or tirzepatide, which have branded FDA-approved versions (Wegovy, Zepbound) with compounded alternatives, AOD-9604 has never completed the FDA approval process for any indication in the United States. The peptide was originally developed by Metabolic Pharmaceuticals in Australia, where Phase IIb trials conducted between 2001 and 2007 evaluated it for obesity treatment at oral doses of 1 mg per day [1].

Those trials did not advance to Phase III registration. A 24-week randomized, double-blind, placebo-controlled study (N=536) found that oral AOD-9604 at 1 mg daily produced modest weight reduction, but the primary efficacy endpoint did not reach statistical significance versus placebo [2]. The program stalled. No pharmaceutical company currently holds a U.S. New Drug Application (NDA) or Investigational New Drug (IND) application for AOD-9604 in an obesity or metabolic indication.

This means there is no "brand-name" version to compare against. Every vial, lozenge, or nasal spray containing AOD-9604 in the U.S. is prepared by a compounding pharmacy operating under either section 503A (patient-specific prescriptions) or section 503B (outsourcing facilities that can produce without individual prescriptions) of the Federal Food, Drug, and Cosmetic Act. The regulatory distinction matters for pricing, quality assurance, and how you actually obtain the peptide.

503A vs. 503B: How the Pharmacy Type Affects Your Cost

The compounding pharmacy category directly determines what you pay. Section 503A pharmacies prepare AOD-9604 for a specific patient based on a valid prescription from a licensed prescriber. Section 503B outsourcing facilities compound in larger batches under current good manufacturing practice (cGMP) conditions and register with the FDA [3].

Pricing at 503A pharmacies for a 30-day supply of injectable AOD-9604 (typically 250 mcg/day, supplied as a multi-dose vial of 5 mg lyophilized powder with bacteriostatic water) ranges from $120 to $250. Geographic variation is real: pharmacies in states with higher compounding overhead, such as California and New York, tend to charge toward the upper end. Pharmacies in Texas and Florida often price between $130 and $180 for the same formulation.

503B outsourcing facilities generally offer lower per-unit costs because batch production is more efficient. Telehealth platforms that partner with 503B facilities frequently advertise AOD-9604 programs at $99 to $180 per month, bundling the peptide with a consultation fee and sometimes bacteriostatic water and syringes. The tradeoff is less customization. A 503A pharmacy can adjust concentration, add combination peptides (such as AOD-9604 with CJC-1295), or prepare alternative delivery forms on a per-patient basis. A 503B facility typically offers a fixed menu of concentrations and doses.

The FDA maintains a list of registered 503B outsourcing facilities that is updated quarterly. Before filling a prescription, verify that the facility appears on this list and check its most recent FDA inspection report for any Form 483 observations related to sterility assurance.

What AOD-9604 Compounded Formulations Look Like in Practice

Most prescriptions specify subcutaneous injectable AOD-9604. The standard presentation is a lyophilized (freeze-dried) powder in a sterile vial, reconstituted with bacteriostatic water before injection. Common concentrations include 2.5 mg/mL and 5 mg/mL after reconstitution, with the vial containing 5 mg or 10 mg of total peptide.

Alternative delivery formats have emerged. Oral troches (sublingual lozenges) containing 250 to 500 mcg of AOD-9604 are available from some 503A pharmacies, though bioavailability is significantly lower than subcutaneous injection. The original Australian clinical trials used an oral capsule formulation and required 1 mg doses to achieve measurable serum levels [2]. Sublingual absorption may partially bypass first-pass hepatic metabolism, but no published pharmacokinetic comparison between sublingual and subcutaneous AOD-9604 exists as of May 2026.

Nasal spray formulations have also appeared at select compounding pharmacies. Pricing for nasal AOD-9604 (typically 500 mcg per spray, 30 sprays per bottle) runs $100 to $200. Absorption data for intranasal AOD-9604 is limited to preclinical models. The Endocrine Society's 2024 clinical practice guideline on peptide therapies does not specifically address AOD-9604 but notes that non-injectable peptide delivery remains an area of active investigation with inconsistent bioavailability across compounds.

For patients who want the most predictable drug exposure, subcutaneous injection remains the standard recommendation. The injection technique is identical to insulin administration: a 29- or 31-gauge, half-inch needle into the abdominal subcutaneous fat, rotated among injection sites.

Insurance Will Not Cover AOD-9604

This is straightforward. No U.S. commercial insurer, Medicare Part D plan, or Medicaid program covers AOD-9604 in any formulation. The reasons are structural, not likely to change soon.

First, AOD-9604 lacks FDA approval. Insurance formularies are built around FDA-approved drugs. The Centers for Medicare & Medicaid Services (CMS) explicitly excludes compounded medications that do not contain at least one FDA-approved ingredient used for an FDA-approved indication. AOD-9604 does not qualify.

Second, compounded peptides broadly are excluded from coverage. Even compounded semaglutide and compounded tirzepatide, which contain FDA-approved active ingredients, face widespread coverage denials. A peptide that has never been approved has zero chance of formulary inclusion under current policy.

Third, no manufacturer-sponsored patient assistance program exists. Programs like Novo Nordisk's savings cards for Wegovy or Eli Lilly's copay assistance for Zepbound exist because a manufacturer has a financial incentive to subsidize access to its branded product. AOD-9604 has no manufacturer, no marketing authorization holder, and no commercial sponsor. There is no coupon to clip.

Patients paying out of pocket should ask their compounding pharmacy about multi-month supply discounts. Some pharmacies offer 10% to 15% price reductions for 90-day supplies paid upfront. Health Savings Account (HSA) and Flexible Spending Account (FSA) funds can sometimes be applied to compounded medications if accompanied by a valid prescription and a letter of medical necessity, though individual plan administrators vary in their interpretation [4].

How to Reduce Your AOD-9604 Costs

Price shopping is the primary tool. Because AOD-9604 is not a controlled substance and can be prescribed by any licensed provider (MD, DO, NP, PA depending on state scope-of-practice laws), patients have flexibility in choosing both their prescriber and their pharmacy.

Compare at least three pharmacies. Prices for the same 5 mg vial of AOD-9604 can differ by $80 or more between pharmacies in the same state. Request an itemized quote that separates the drug cost from dispensing fees, shipping, and consultation charges. Some telehealth platforms bundle all costs; others charge separately.

Ask about combination vials. If your prescriber has recommended AOD-9604 alongside another peptide (BPC-157, for example), a single combination vial is typically cheaper than two separate vials. A compounded AOD-9604/BPC-157 combination vial (5 mg/5 mg) runs $180 to $300 at most 503A pharmacies, compared to $120 to $250 for AOD-9604 alone plus $100 to $200 for BPC-157 alone.

Consider dose optimization. The commonly prescribed 500 mcg/day dose is based on extrapolation from animal data showing lipolytic effects at that range. The human trial data used 1 mg oral, which is not directly comparable to subcutaneous dosing [2]. Some clinicians start at 250 mcg/day and titrate based on response, which halves the monthly peptide cost. Discuss dose-finding with your prescriber rather than defaulting to the highest commonly advertised dose.

Evaluate telehealth bundled programs. Several telehealth platforms that specialize in peptide therapy offer monthly subscription models that include the prescription, clinical oversight, and the compounded product. These bundles typically range from $149 to $249 per month. The per-unit drug cost within a bundle may be lower than purchasing from an independent 503A pharmacy, but you lose the ability to choose your own pharmacy.

Purity and Potency: What to Verify Before You Buy

Because AOD-9604 is only available as a compounded product, quality varies between pharmacies. The FDA's guidance on compounding quality emphasizes that compounded drugs are not FDA-approved and do not undergo the same premarket review as manufactured drugs.

Key quality indicators to request from your compounding pharmacy:

Certificate of Analysis (COA) for the raw peptide. The COA should show peptide purity of 98% or higher by HPLC (high-performance liquid chromatography), endotoxin testing results below 0.25 EU/mL for injectable preparations, and amino acid sequence verification confirming the correct 16-amino-acid fragment (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe).

Beyond-use dating (BUD). USP <797> standards, revised in November 2023, set maximum BUDs for compounded sterile preparations based on the pharmacy's testing capabilities [5]. For a reconstituted AOD-9604 vial stored under refrigeration (2 to 8°C), most 503A pharmacies assign a 28-day BUD. Some 503B facilities with extended sterility testing can assign 60- to 90-day BUDs, which may allow patients to purchase less frequently.

Third-party testing. A small but growing number of compounding pharmacies voluntarily submit finished products to independent labs like Analytical Resource Laboratories or Eagle Analytical Services. Ask whether the pharmacy participates in voluntary third-party potency and sterility verification.

Dr. Christina Madison, PharmD, a compounding pharmacy specialist and faculty member at Roseman University, has noted: "Patients should treat compounded peptides the same way they would treat any injectable medication. Ask to see the COA, verify the pharmacy's accreditation status with PCAB or their state board, and never purchase from a source that cannot provide documentation of sterility testing."

The Regulatory Picture for Compounded AOD-9604 in 2026

The FDA's approach to compounded peptides has shifted significantly since 2023. In October 2023, the agency added tirzepatide to its drug shortage list, which temporarily opened the door for 503A and 503B pharmacies to compound it. When tirzepatide was removed from the shortage list in late 2024, the FDA issued cease-and-desist communications to compounders, triggering legal challenges that remain active.

AOD-9604 occupies a different regulatory niche because it was never FDA-approved in the first place. The FDA's authority over compounded versions rests on whether AOD-9604 appears on the agency's "bulk drug substances" list under section 503B or qualifies for compounding under the "clinical need" provisions of 503A. As of May 2026, AOD-9604 is not on the FDA's list of bulk drug substances that may be used in compounding under section 503B. This means 503B outsourcing facilities technically face greater regulatory risk in producing it than 503A pharmacies do.

The Pharmacy Compounding Advisory Committee (PCAC) has not yet reviewed AOD-9604 for inclusion on the 503B bulks list. If it does, and if the committee votes against inclusion, 503B production could cease, pushing all supply to 503A pharmacies and likely increasing prices. Patients currently using a 503B-sourced product should be aware of this regulatory uncertainty.

"The peptide compounding space is moving faster than the regulatory apparatus can respond," said Dr. Peter Attia, MD, in a January 2026 episode of The Drive podcast. "Patients need to understand that access to specific peptides through compounding could change with 90 days' notice or less."

What AOD-9604 Is Prescribed For (and What the Evidence Actually Shows)

Most prescriptions for AOD-9604 cite fat reduction or body composition improvement as the clinical rationale. The peptide is a modified fragment of human growth hormone (amino acids 176 through 191, with a tyrosine substitution at position 182) that retains the lipolytic activity of full-length GH without its diabetogenic or growth-promoting effects [6].

The preclinical evidence is more strong than the clinical evidence. In obese Zucker rats, AOD-9604 reduced body fat by 50% over 19 days at doses of 500 mcg/kg/day without affecting IGF-1 levels or glucose tolerance [6]. Human data is limited to the Australian Phase IIb program. The largest published trial (N=536) randomized participants to oral AOD-9604 at 0.25 mg, 0.5 mg, or 1 mg daily versus placebo for 24 weeks [2]. The 1 mg group lost 1.6 kg more than placebo, a difference that was not statistically significant (p=0.12).

This is a thin evidence base for a peptide that costs $150+ per month out of pocket. The Endocrine Society has not included AOD-9604 in its obesity management guidelines. No head-to-head trials compare AOD-9604 to semaglutide, tirzepatide, or any other approved anti-obesity medication. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% for placebo [7]. AOD-9604's clinical results do not approach this magnitude.

Prescribers who recommend AOD-9604 typically position it as an adjunctive therapy alongside diet, exercise, and sometimes in combination with GLP-1 receptor agonists, rather than as a standalone weight-loss treatment. Patients should have a frank conversation with their clinician about the strength of the evidence relative to the cost.

Storage, Reconstitution, and Handling

Lyophilized AOD-9604 vials should be stored at controlled room temperature (20 to 25°C) before reconstitution. Once reconstituted with bacteriostatic water, store the vial refrigerated at 2 to 8°C. Do not freeze reconstituted solution.

Reconstitution steps: draw the prescribed volume of bacteriostatic water (typically 1 mL per 5 mg vial for a 5 mg/mL concentration) and inject it slowly down the inside wall of the vial. Do not shake. Swirl gently until the powder dissolves completely. The solution should be clear and colorless. Discard if particulate matter or discoloration is visible. Use within the BUD assigned by the pharmacy, typically 28 days from reconstitution for 503A preparations [5].

Draw the prescribed dose using an insulin syringe. For a 250 mcg dose from a 5 mg/mL solution, draw 0.05 mL (5 units on a U-100 insulin syringe). For 500 mcg, draw 0.1 mL (10 units). Inject subcutaneously into the abdomen, rotating sites by at least 1 inch between injections. Most prescribers recommend morning dosing on an empty stomach, based on the rationale that fasting-state lipolysis may be potentiated, though this timing preference is extrapolated from GH physiology rather than AOD-9604-specific data.